Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Pulmonx Corp’s stock clocked out at $3.11, down -0.32% from its previous closing price of $3.12. In other words, the price has decreased by -$0.32 from its previous closing price. On the day, 0.23 million shares were traded. LUNG stock price reached its highest trading level at $3.13 during the session, while it also had its lowest trading level at $2.97.
Ratios:
To gain a deeper understanding of LUNG’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.29 and its Current Ratio is at 4.97. In the meantime, Its Debt-to-Equity ratio is 0.73 whereas as Long-Term Debt/Eq ratio is at 0.62.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, D. Boral Capital on March 10, 2025, initiated with a Buy rating and assigned the stock a target price of $17.
On December 11, 2024, Citigroup Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $17 to $7.50.
On June 04, 2024, Lake Street started tracking the stock assigning a Buy rating and target price of $12.Lake Street initiated its Buy rating on June 04, 2024, with a $12 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 20 ’25 when French Glendon E. III sold 20,000 shares for $7.85 per share. The transaction valued at 157,000 led to the insider holds 991,974 shares of the business.
GLENDON FRENCH bought 60,000 shares of LUNG for $466,200 on Mar 20 ’25. On Mar 03 ’25, another insider, Joshi Mehul, who serves as the Chief Financial Officer & PAO of the company, sold 14,384 shares for $7.12 each. As a result, the insider received 102,414 and left with 113,986 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LUNG now has a Market Capitalization of 125200824 and an Enterprise Value of 93447912. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.43 while its Price-to-Book (P/B) ratio in mrq is 1.61. Its current Enterprise Value per Revenue stands at 1.068 whereas that against EBITDA is -1.709.
Stock Price History:
The Beta on a monthly basis for LUNG is 0.54, which has changed by -0.61173534 over the last 52 weeks, in comparison to a change of 0.09362543 over the same period for the S&P500. Over the past 52 weeks, LUNG has reached a high of $9.37, while it has fallen to a 52-week low of $3.06. The 50-Day Moving Average of the stock is -40.48%, while the 200-Day Moving Average is calculated to be -52.06%.
Shares Statistics:
It appears that LUNG traded 359.17K shares on average per day over the past three months and 314440 shares per day over the past ten days. A total of 40.25M shares are outstanding, with a floating share count of 35.32M. Insiders hold about 12.26% of the company’s shares, while institutions hold 85.92% stake in the company. Shares short for LUNG as of 1745971200 were 1193348 with a Short Ratio of 3.32, compared to 1743379200 on 1234912. Therefore, it implies a Short% of Shares Outstanding of 1193348 and a Short% of Float of 4.37.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current assessment of Pulmonx Corp (LUNG) involves the perspectives of 7.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.39, with high estimates of -$0.37 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$1.49 and -$1.59 for the fiscal current year, implying an average EPS of -$1.54. EPS for the following year is -$1.39, with 7.0 analysts recommending between -$1.18 and -$1.55.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $23.46M. It ranges from a high estimate of $23.8M to a low estimate of $23.28M. As of the current estimate, Pulmonx Corp’s year-ago sales were $20.78MFor the next quarter, 7 analysts are estimating revenue of $23.77M. There is a high estimate of $24.25M for the next quarter, whereas the lowest estimate is $23.3M.
A total of 7 analysts have provided revenue estimates for LUNG’s current fiscal year. The highest revenue estimate was $97.47M, while the lowest revenue estimate was $96M, resulting in an average revenue estimate of $97.02M. In the same quarter a year ago, actual revenue was $83.79MBased on 7 analysts’ estimates, the company’s revenue will be $114.52M in the next fiscal year. The high estimate is $118.25M and the low estimate is $110.4M.
